SecBot SecBot
SECBOTREPLAY Home › Report › HALO

HALO · PTAB cancels key Halozyme patent

HALOZYME THERAPEUTICS, INC. · PTAB-TRIAL filed Nov 8, 2026 at 19:00 ET

At the news

BEARISHIMPACT 6/10

PTAB-TRIAL filed Nov 8, 2026 at 19:00 ET

The PTAB issued a final written decision in PGR2025-00042, holding all challenged claims (1, 2, 5, and 7–33) of Halozyme's U.S. Patent 12,037,618 unpatentable for lack of written description, lack of enablement, and obviousness. The patent covers modified PH20 hyaluronidase polypeptides, which are central to Halozyme's drug delivery technology platform. This is a material loss for Halozyme, as the patent is part of a broader patent family asserted against Merck in a related district court litigation.

  • Final Written Decision in PGR2025-00042 cancels all challenged claims (1, 2, 5, 7–33) of U.S. Patent 12,037,618 B2
  • Patent covers modified PH20 hyaluronidase polypeptides used in drug delivery
  • Petitioner Merck Sharp & Dohme LLC prevailed on all three grounds: written description, enablement, and obviousness
  • Patent is part of a family of 15+ related patents asserted in Halozyme v. Merck (2:25-cv-03179 D.N.J.)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access